Navigation Links
FDA, CMS Launch Pilot Program for Voluntary Parallel Review of Innovative Devices
Date:10/7/2011

SILVER SPRING, Md., Oct. 7, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration and the Centers for Medicare & Medicaid Services (CMS) today launched a "parallel review" pilot program for concurrent review of medical devices for FDA approval and Medicare coverage.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The FDA and CMS, which will begin accepting submissions today, issued procedures for voluntary participation and guiding principles that the agencies will follow during product review. The FDA and CMS anticipate that parallel review will facilitate the development of innovative new products and increase the efficiency of the review processes for both agencies.

"The pilot program will help the FDA and CMS streamline the parallel review process so that it works efficiently for expedient patient access to safe and effective medical devices," said Jeffrey Shuren, M.D., director of the FDA's Center for Devices and Radiological Health.

Often, device sponsors focus solely on obtaining FDA approval, only to find that Medicare coverage is not automatically forthcoming. Both agencies rely on clinical data in reaching their decisions, and while the two agencies have distinctly different regulatory responsibilities, parallel review can reduce time between FDA approval and Medicare national coverage determinations.

"The parallel review program has the potential to increase patient access to innovative devices that improve clinical outcomes. Our goal is to reduce regulatory burden and improve patient outcomes," said Patrick Conway, M.D., CMS chief medical officer.

The pilot program, announced in a Federal Register notice posted for advanced viewing today, is voluntary and will not change the existing separate and distinct review standards for FDA device approval and CMS coverage determination. It is only available for qualifying new medical device technologies.  

The Federal Register notice also outlines the agencies' commitment to ensuring that submitted data is confidential and highlights when sponsors can opt-out of the parallel review program.  

The pilot program, which will last for up to two years with the possibility for extension, will focus on innovative technologies that can benefit from the efficiencies of parallel review. The pilot program will accept no more than three to five submissions per year.

In September 2010, the FDA and CMS announced their intention to implement a parallel review process, and received 37 public comments, which can be found in the public docket.

For more information and to read the Federal Register notice:

FDA-CMS Premarket Review

http://www.fda.gov/parallel-review.

Medicare Coverage Center

http://www.cms.gov/center/coverage.asp

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

For Immediate Release: Oct. 7, 2011
Media Inquiries: FDA – Karen Riley, 301-796-4674, karen.riley@fda.hhs.gov;
CMS – Media Relations Group, 202-690-6145, OEABox@cms.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CelsyaLife.com Set to Launch at "Walk to End Alzheimers"
2. New Report Details Launch Investment Levels for Pharmaceutical Industry
3. In Honor of National Breast Cancer Awareness Month, Alma Lasers Launches Nationwide Radiation Tattoo Removal Program, Declare Your Freedom
4. Incisive Surgical Launches New National Patient Advocacy Campaign -- Eliminate Traumatic Metal Skin Staples for Routine Skin Closure
5. EMDT Launches New Specialist Conference on Managing Regulatory Change for Medical Devices
6. voiceTech Launches ServiceLink-Rx, the First Comprehensive Patient Communication Platform for Retail Pharmacies
7. ICU Medical Launches Neutron™ Needlefree Catheter Patency Device With Constant Neutral Pressure Backed by a $100,000 Guarantee to Reduce Catheter Occlusions
8. Hikma Enters the Moroccan Market Through the Acquisition of 63.9% of Promopharm and Will Launch a Mandatory Tender Offer for the Remaining 36.1%
9. Ventus Medical Launches Provent® Sleep Apnea Therapy in Australia and New Zealand
10. Brain Resource Launches MyCalmBeat Personal Stress Reduction Monitor at Health 2.0
11. Reiki Awakening Academy Launches Online Innovative Face-to-Face Intuitive Development on the Internet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)...  Marking its one year anniversary since launching ... risk test, Color Genomics announced a ... impact the most common hereditary cancers affecting both ... analyzes hereditary cancer risks for breast, colorectal, melanoma, ... Color Test is physician ordered and includes genetic ...
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
Breaking Medicine Technology:
(Date:4/29/2016)... York, NY (PRWEB) , ... April 29, 2016 , ... New York City based oral ... . This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... print media enterprise focused entirely on patients with cancer, today announced that Lynne ... chosen as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in the ... of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott ...
Breaking Medicine News(10 mins):